Homepage
Medication Guide
What are the Precautions for Lorlatinib (Lorviqua) Administration?
Lorlatinib (Lorviqua) is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that has demonstrated breakthrough efficacy in the treatment of ALK-positive non-small cell lung ...
510
Thursday, January 8th, 2026, 13:05
Dosage and Administration, Recommended Dose of Lorlatinib (Lorviqua)
Lorlatinib (Lorviqua), a third-generation ALK inhibitor, demonstrates remarkable efficacy in the treatment of ALK-positive non-small cell lung cancer (NSCLC).Dosage and Administration, Recommended Dos...
506
Thursday, January 8th, 2026, 13:03
What Are the Indications of Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an important isocitrate dehydrogenase-1 (IDH1) inhibitor, providing an innovative treatment option for patients with various malignant tumors harboring IDH1 mutations.What Are ...
513
Wednesday, January 7th, 2026, 11:50
What Are the Indications for Lorlatinib (Lorviqua)?
Lorlatinib (Lorviqua) is an oral tyrosine kinase inhibitor primarily indicated for the treatment of specific types of non-small cell lung cancer (NSCLC). It provides a crucial therapeutic option for p...
510
Wednesday, January 7th, 2026, 11:42
Channels for Purchasing Lorlatinib (Lorviqua)
Lorlatinib (Lorviqua) is a third-generation ALK inhibitor, offering an important treatment option for lung cancer patients. How to obtain the medication safely and in compliance with regulations, whil...
508
Wednesday, January 7th, 2026, 11:38
Dosage, Administration and Recommended Dose of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is the first targeted therapy indicated for acute myeloid leukemia (AML) with IDH1 mutations, and its standardized administration is crucial for treatment efficacy.Dosage, Adminis...
508
Wednesday, January 7th, 2026, 11:32
Channels for Purchasing Tibsovo® (Ivosidenib)
Tibsovo® (Ivosidenib) is an oral targeted therapy indicated for IDH1 mutations. It has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of specific types of acute myeloid...
508
Wednesday, January 7th, 2026, 11:24
Adverse Reactions of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET kinase inhibitor that has become an important targeted therapy for the treatment of metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 ...
521
Tuesday, January 6th, 2026, 10:15
What Are the Precautions for Capmatinib (Tabrecta) Administration?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that offers a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutati...
506
Tuesday, January 6th, 2026, 10:13
Dosage and Administration, Recommended Dose of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is the world’s first approved targeted therapy for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. Rational administration of this medicat...
506
Tuesday, January 6th, 2026, 10:11
26 / 214
2139 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved